Previous close | 83.58 |
Open | 82.44 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 82.02 - 83.20 |
52-week range | 66.64 - 88.78 |
Volume | |
Avg. volume | 202,013 |
Market cap | N/A |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
UCB, a global biopharmaceutical company, today announced that the first presentations of BIMZELX® (bimekizumab-bkzx) four-year efficacy and safety data in the treatment of adults with moderate-to-severe plaque psoriasis are being shared this week at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, March 8–12.
UCB, a global biopharmaceutical company, today announced 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies examining the impact of BIMZELX on skin pain and draining tunnels in adults with moderate-to-severe hidradenitis suppurativa (HS). These results are shared at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, March 8–12.